The latest report by IMARC Group, titled “Digital Dose Inhaler Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” finds that the global digital dose inhaler market size reached US$ 2.49 Billion in 2021. A digital dose inhaler is a device that delivers a specific amount of medication to the lungs in the form of aerosolized medicine to asthma and chronic obstructive pulmonary disease (COPD) patients. It is a simplified and reliable dose counter with a display at the completion of the labeled therapeutic aerosol spray. In recent years, digital dose inhaler has gained immense popularity as it comprises sensors that record medication administration time and provide a low-dose warning indicator.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global Digital Dose Inhaler Market Trends:
The increasing incidences of chronic respiratory diseases, such as asthma, obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), and other respiratory allergies, represents the primary factor bolstering the market growth. Besides this, several initiatives undertaken by the governing agencies of numerous countries to spread awareness about the benefits of hi-tech respiratory devices are also catalyzing the product demand. Moreover, several technological advancements, such as the introduction of inhalation therapy devices, such as digital dose inhalers equipped with an e-dose counter, internet-connected, and compact inhalers, are providing a positive outlook to the market. Furthermore, the onset of coronavirus disease (COVID-19), growing geriatric population, rising pollution levels, increasing tobacco consumption are some of the other factors expected to drive the digital dose inhalers market. Looking forward, the market is projected to grow at a CAGR of 15.1% during the forecast period (2022-2027).
- Based on the type, the market has been segmented into branded and generic medications.
- On the basis of the product, the market has been segregated into metered-dose and dry powder inhalers.
- Region-wise, the market has been segmented into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
- The competitive landscape of the market has also been examined, with some of the key players being 3M Company, AstraZeneca plc, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Koninklijke Philips N.V., Lupin Limited, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG Switzerland and Teva Pharmaceutical Industries Ltd.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800